Loading...
XSHE002390
Market cap951mUSD
Jan 14, Last price  
3.92CNY
1D
1.03%
1Q
13.95%
Jan 2017
-60.36%
IPO
-17.30%
Name

Guizhou Xinbang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002390 chart
P/E
24.30
P/S
1.08
EPS
0.16
Div Yield, %
1.67%
Shrs. gr., 5y
3.39%
Rev. gr., 5y
-0.37%
Revenues
6.46b
+1.75%
173,328,371217,753,605274,743,391336,685,856318,627,651361,864,803447,572,062569,487,9222,476,183,0594,179,756,0995,157,031,7756,002,471,0306,580,278,9186,655,063,5775,845,621,5256,471,866,3346,350,025,8276,460,841,314
Net income
287m
+28.02%
17,450,89829,911,23833,613,68646,416,22737,757,39346,078,75347,828,99040,237,319144,770,445174,379,440246,012,798319,383,5010236,301,518173,521,475373,955,063224,374,022287,232,798
CFO
791m
+33.82%
032,485,80024,860,89241,753,1232,500,7310000217,402,1650201,742,9490886,327,517742,111,911457,971,988590,796,585790,618,030
Dividend
May 17, 20240.06 CNY/sh
Earnings
May 08, 2025

Profile

Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.
IPO date
Apr 16, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,460,841
1.75%
6,350,026
-1.88%
Cost of revenue
5,631,100
5,677,558
Unusual Expense (Income)
NOPBT
829,742
672,468
NOPBT Margin
12.84%
10.59%
Operating Taxes
42,249
44,977
Tax Rate
5.09%
6.69%
NOPAT
787,493
627,491
Net income
287,233
28.02%
224,374
-40.00%
Dividends
(116,631)
(116,631)
Dividend yield
1.37%
1.28%
Proceeds from repurchase of equity
(141,401)
BB yield
1.66%
Debt
Debt current
796,285
1,345,754
Long-term debt
42,249
44,046
Deferred revenue
22,039
18,886
Other long-term liabilities
308
(238)
Net debt
(307,921)
146,781
Cash flow
Cash from operating activities
790,618
590,797
CAPEX
(135,781)
Cash from investing activities
50,259
(118,021)
Cash from financing activities
(908,180)
FCF
1,142,760
655,092
Balance
Cash
805,983
899,181
Long term investments
340,472
343,839
Excess cash
823,413
925,518
Stockholders' equity
2,966,898
2,763,307
Invested Capital
7,158,431
7,492,673
ROIC
10.75%
8.34%
ROCE
10.39%
7.99%
EV
Common stock shares outstanding
1,914,885
1,943,852
Price
4.44
-5.53%
4.70
-36.66%
Market cap
8,502,091
-6.94%
9,136,104
-32.31%
EV
8,483,855
9,539,481
EBITDA
1,066,452
916,014
EV/EBITDA
7.96
10.41
Interest
40,485
51,788
Interest/NOPBT
4.88%
7.70%